| Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
| 2011 | A Cullin3-KLHL20 Ubiquitin Ligase-Dependent Pathway Targets PML to Potentiate HIF-1 Signaling and Prostate Cancer Progression | Yuan, WC; Lee, YR ; Huang, SF; Lin, YM; Chen, TY; Chung, HC; Tsai, CH; Chen, HY; Chiang, CT; Lai, CK; Lu, LT; Chen, CH; Gu, DL; Pu, YS; Jou, YS ; Lu, KP; Hsiao, PW ; Shih, HM ; Chen, RH | Cancer cell 20(2), 214-228 | | | |
| 2011 | A Cullin3-KLHL20 ubiqutin ligase-dependent pathway targets PML to amplify HIF-1 signaling and tumor hypoxia responses. | Yuan, WC; Lee, YR; Huang, SF; Lin, YM; Chen, TY; Chung, HC; Tsai, CH; Chen, HY; Chiang, CT; Lai, CK; Lu, LT; Chen, CH; Gu, DL; Pu, YS; Jou, YS; Lu, KP; Hsiao, PW; Shih, HM; Chen, RH. | CANCER CELL 20, 214-228 | | | |
| 2008 | Androgen receptor gene polymorphism may affect the risk of urothelial carcinoma. | Liu, CH; Huang, JD; Huang, SW; Hour, TC; Huang, YK; Hsueh, YM; Chiou, HY; Lee, TC; Jan, KY; Chen, CJ; Pu, YS | Journal of biomedical science 15(2), 261-269 | | | |
| 2009 | Arsenic methylation capability, myeloperoxidase and sulfotransferase genetic polymorphisms, and the stage and grade of urothelial carcinoma | Huang, SK; Chiu, AW; Pu, YS; Huang, YK; Chung, CJ; Tsai, HJ; Yang, MH; Chen, CJ; Hsueh, YM | Urol Int 82,227-234 | | | |
| 2009 | Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in Taiwan | Chen, CH; Chiou, HY; Hsueh, YM; Chen, CJ; Yu, HJ; Pu, YS | J Urol 181, 547-552 | | | |
| 2013 | Comparing the joint effect of arsenic exposure, cigarette smoking and risk genotypes of vascular endothelial growth factor on upper urinary tract urothelial carcinoma and bladder cancer | Wang, YH; Yeh, SD; Wu, MM; Liu, CT; Shen, CH; Shen, KH; Pu, YS; Hsu, LI; Chiou, HY; Chen, CJ | Journal of Hazardous Materials | | | |
| 2017 | Promoter hypermethylation of LGALS4 correlates with poor prognosis in patients with urothelial carcinoma | Wu, MM; Li, CF; Lin, LF; Wang, AS; Pu, YS; Wang, HH; Mar, AC; Chen, CJ ; Lee, TC | Oncotarget 8(14), 23787-23802 | | | |
